Literature DB >> 15924142

Temporal dissection of p53 function in vitro and in vivo.

Maria A Christophorou1, Dionisio Martin-Zanca, Laura Soucek, Elizabeth R Lawlor, Lamorna Brown-Swigart, Emmy W Verschuren, Gerard I Evan.   

Abstract

To investigate the functions of the p53 tumor suppressor, we created a new knock-in gene replacement mouse model in which the endogenous Trp53 gene is substituted by one encoding p53ER(TAM), a p53 fusion protein whose function is completely dependent on ectopic provision of 4-hydroxytamoxifen. We show here that both tissues in vivo and cells in vitro derived from such mice can be rapidly toggled between wild-type and p53 knockout states. Using this rapid perturbation model, we define the kinetics, dependence, persistence and reversibility of p53-mediated responses to DNA damage in tissues in vivo and to activation of the Ras oncoprotein and stress in vitro. This is the first example to our knowledge of a new class of genetic model that allows the specific, rapid and reversible perturbation of the function of a single endogenous gene in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15924142     DOI: 10.1038/ng1572

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  101 in total

Review 1.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

Review 2.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 3.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

4.  Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; María Jiménez; Latifa Bakiri; Peter Petzelbauer; Erwin F Wagner
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

5.  Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Authors:  Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

6.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Authors:  Anastasia R Goloudina; Kan Tanoue; Arlette Hammann; Eric Fourmaux; Xavier Le Guezennec; Dmitry V Bulavin; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

7.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

8.  p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice.

Authors:  Talía Velasco-Hernández; Carolina Vicente-Dueñas; Isidro Sánchez-García; Dionisio Martin-Zanca
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 9.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

10.  p53: a molecular marker for the detection of cancer.

Authors:  Mark T Boyd; Nikolina Vlatkovic
Journal:  Expert Opin Med Diagn       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.